Skip to content

Released Feb 27, 2025, after the close

10-K filed Feb 28, 2025, 59 days after period end · 0001628280-25-008780

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$57.48Mderived−1.3% vs Q4 2023+11.6% vs Q3 2024
Net Income$9.64Mderived+75.2% vs Q4 2023+924.7% vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$33,652,000+1.8%
Operating Incomederived$2,986,000N/M
Operating Cash Flowderived$1,997,000−79.0%
Free Cash Flowderived$1,103,000−86.2%
Margins · derived
Gross margin58.5%+1.8 pt vs Q4 2023
Operating margin5.2%+5.4 pt vs Q4 2023
Net margin16.8%+7.3 pt vs Q4 2023

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$57.48M$58.23M$48.34M$38.89M
Net Income$9.64M$5.50M$3.72M-$1.17M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR